ADM 12 is a highly selective transient receptor potential ankyrin 1 ( TRPA1 ) channel antagonist. ADM 12 blocks nitroglycerin (NTG)-induced trigeminal hyperalgesia in animal models, reducing expression of pain-related genes ( c-Fos, TRPA1 ) and neuropeptides (CGRP, SP). ADM_12 is promising for research of migraine and neuropathic pain [1].
References:
[1]. Demartini C, et al. The role of the transient receptor potential ankyrin type-1 (TRPA1) channel in migraine pain: evaluation in an animal model. J Headache Pain. 2017 Sep 7;18(1):94.
References:
[1]. Demartini C, et al. The role of the transient receptor potential ankyrin type-1 (TRPA1) channel in migraine pain: evaluation in an animal model. J Headache Pain. 2017 Sep 7;18(1):94.